ABEO
NASDAQAbeona Therapeutics Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
News · 26 weeks52-29%
2026-04-192026-10-11
Mix2090d
- Other8(40%)
- Insider6(30%)
- SEC Filings3(15%)
- Earnings2(10%)
- Analyst1(5%)
Latest news
25 items- PRAbeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CLEVELAND, Ohio, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). On September 30, 2026, the Compensation Committee of Abeona’s Board of Directors granted restricted stock equity awards as a material inducement to employment to two individuals hired by Abeona, which equity awards relate to, in the aggregate, up to 7,200 restricted shares of Abeona common stock. One-third of the shares subject to such restricted stock awards is scheduled to vest yearly on each anniversary of the Grant D
- INSIDERChief Executive Officer Seshadri Vishwas sold $101,091 worth of shares (19,608 units at $5.16), decreasing direct ownership by 2% to 1,286,500 units (SEC Form 4) to satisfy tax liability4 - ABEONA THERAPEUTICS INC. (0000318306) (Issuer)
- INSIDERChief Financial Officer Vazzano Joseph Walter sold $47,385 worth of shares (9,191 units at $5.16), decreasing direct ownership by 2% to 482,888 units (SEC Form 4) (withholding obligation)4 - ABEONA THERAPEUTICS INC. (0000318306) (Issuer)
- INSIDERSVP, Chief Legal Officer O'Malley Brendan M. sold $34,682 worth of shares (6,727 units at $5.16), decreasing direct ownership by 2% to 421,226 units (SEC Form 4) (for tax liability)4 - ABEONA THERAPEUTICS INC. (0000318306) (Issuer)
- INSIDERChief Commercial Officer Vasanthavada Madhav sold $25,273 worth of shares (4,902 units at $5.16), decreasing direct ownership by 2% to 285,721 units (SEC Form 4) to satisfy withholding tax4 - ABEONA THERAPEUTICS INC. (0000318306) (Issuer)
- PRAbeona Therapeutics® Congratulates Ultragenyx on U.S. FDA Approval of FAYUVI™ Gene Therapy for Sanfilippo Syndrome Type A (MPS IIIA)- FDA approval represents a monumental milestone for patients with MPS IIIA and validates Abeona’s foundational R&D and clinical development efforts - - Ultragenyx successfully brought a life-changing therapy across the finish line for MPS IIIA patients and families - CLEVELAND, Sept. 18, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a commercial-stage biopharmaceutical company developing genetic medicines for serious diseases with high unmet need, today congratulated Ultragenyx Pharmaceutical Inc., on the U.S. Food and Drug Administration (FDA) approval of FAYUVI™ (rebisufligene etisparvovec-hopf), also known as UX111, a gene therapy for the treatment of patients with
- ANALYSTRoth Capital initiated coverage on Abeona Therapeutics with a new price targetRoth Capital initiated coverage of Abeona Therapeutics with a rating of Buy and set a new price target of $17.00
- PRAbeona Therapeutics® Announces Activation of University of Florida Health as Newest Qualified Treatment Center for ZEVASKYN®CLEVELAND, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a commercial-stage biopharmaceutical company developing genetic medicines for serious diseases with high unmet need, today announced the activation of University of Florida Health (UF Health) in Gainesville, Florida, as the eighth Qualified Treatment Center (QTC) for the administration of ZEVASKYN (prademagene zamikeracel) gene-modified cellular sheets. ZEVASKYN is the first and only autologous gene-modified cellular sheets for the treatment of wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB). "Activation of UF Health as a QTC represents an important step in expanding access to Z
- SECAbeona Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - ABEONA THERAPEUTICS INC. (0000318306) (Filer)
- PRAbeona Therapeutics® Announces Participation in Upcoming Investor ConferencesCLEVELAND, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) today announced that members of its management team will participate in upcoming investor conferences in September 2026: Cantor Global Healthcare Conference 2026: Fireside chat on Wednesday, September 9, 2026, at 8:00 a.m. ET and investor meetings.H.C. Wainwright 28th Annual Global Investment Conference: Company presentation on Tuesday, September 15, 2026, at 12:00 p.m. ET and investor meetings.Morgan Stanley 24th Annual Global Healthcare Conference: Fireside chat on Wednesday, September 16, 2026, at 11:30 a.m. ET and investor meetings. Live webcasts of the fireside chats and company presentation can be
- INSIDERDirector Alvino Mark sold $87,966 worth of shares (15,000 units at $5.86), decreasing direct ownership by 19% to 62,065 units (SEC Form 4)4 - ABEONA THERAPEUTICS INC. (0000318306) (Issuer)
- PRAbeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CLEVELAND, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). On August 31, 2026, the Compensation Committee of Abeona’s Board of Directors granted restricted stock equity awards as a material inducement to employment to five individuals hired by Abeona, which equity awards relate to, in the aggregate, up to 13,300 restricted shares of Abeona common stock. One-third of the shares subject to such restricted stock awards is scheduled to vest yearly on each anniversary of the Grant Date, s
- SECSEC Form 10-Q filed by Abeona Therapeutics Inc.10-Q - ABEONA THERAPEUTICS INC. (0000318306) (Filer)
- SECAbeona Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - ABEONA THERAPEUTICS INC. (0000318306) (Filer)
- PRAbeona Therapeutics® Reports Second Quarter 2026 Results and Provides Business Update- Q2 net ZEVASKYN® revenue increased 31% quarter-over-quarter to $11.4 million – - Five patients treated with ZEVASKYN in Q2 2026 and three treatments in Q3 2026 to-date; since launch, 12 treatments completed – - Expanding QTC network now includes seven sites nationwide; growing number of QTCs progressing patients through treatment process – - $146.8 million in cash, cash equivalents and short-term investments as of June 30, 2026 – CLEVELAND, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) today reported financial results for the second quarter of 2026 and provided an update on commercial execution for ZEVASKYN (prademagene zamikeracel). Commercial UpdateStead
- PRAbeona Therapeutics® to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026CLEVELAND, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) today announced that the Company will host a conference call on Thursday, August 13, 2026 at 8:30 a.m. ET to discuss its financial results for the second quarter of 2026 and provide a corporate update. Abeona will announce its financial results for this period in a press release to be issued prior to the call. To access the live conference call, please dial 888-506-0062 (U.S. toll-free) or 973-528-0011 (international) and enter Entry Code: 245916 approximately five minutes prior to the start of the call. A live, listen-only webcast and archived replay of the call can be accessed within the Investors & Med
- PRCMS Grants New Technology Add-On Payment (NTAP) Status for ZEVASKYN®CLEVELAND, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases, today announced that the Centers for Medicare & Medicaid Services (CMS) has granted New Technology Add-On Payment (NTAP) status for ZEVASKYN (prademagene zamikeracel) under the Fiscal Year 2027 Hospital Inpatient Prospective Payment System (IPPS) Final Rule. NTAP status provides supplemental CMS reimbursement above standard hospital payments to support access to innovative therapies like ZEVASKYN. This additional funding is awarded to technologies that meet CMS criteria, including demonstrating substantia
- PRAbeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CLEVELAND, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). On July 31, 2026, the Compensation Committee of Abeona’s Board of Directors granted restricted stock equity awards as a material inducement to employment to two individuals hired by Abeona, which equity awards relate to, in the aggregate, up to 10,800 restricted shares of Abeona common stock. One-third of the shares subject to such restricted stock awards is scheduled to vest yearly on each anniversary of the Grant Date, such
- INSIDERChief Financial Officer Vazzano Joseph Walter sold $9,651 worth of shares (1,478 units at $6.53), decreasing direct ownership by 0.30% to 492,079 units (SEC Form 4) to satisfy withholding tax4 - ABEONA THERAPEUTICS INC. (0000318306) (Issuer)
- PRCincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®CLEVELAND, July 21, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases, today announced the activation of Cincinnati Children’s as the seventh Qualified Treatment Center (QTC) for the administration of ZEVASKYN® (prademagene zamikeracel), the first and only autologous gene-modified cellular sheets for the treatment of wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB). "Cincinnati Children's is one of largest EB centers in the US and we are thrilled to announce its activation as a ZEVASKYN QTC. We look forward to collaborating with Cincinnati Children’s
- SECSEC Form 424B3 filed by Abeona Therapeutics Inc.424B3 - ABEONA THERAPEUTICS INC. (0000318306) (Filer)
- INSIDERChief Financial Officer Vazzano Joseph Walter sold $173,257 worth of shares (24,880 units at $6.96), decreasing direct ownership by 5% to 493,557 units (SEC Form 4) (withholding tax)4 - ABEONA THERAPEUTICS INC. (0000318306) (Issuer)
- INSIDERChief Executive Officer Seshadri Vishwas sold $473,330 worth of shares (67,971 units at $6.96), decreasing direct ownership by 5% to 1,306,108 units (SEC Form 4) to satisfy withholding tax4 - ABEONA THERAPEUTICS INC. (0000318306) (Issuer)
- INSIDERSVP, Chief Legal Officer O'Malley Brendan M. sold $83,913 worth of shares (12,050 units at $6.96), decreasing direct ownership by 3% to 427,953 units (SEC Form 4) to cover taxes4 - ABEONA THERAPEUTICS INC. (0000318306) (Issuer)
- INSIDERChief Commercial Officer Vasanthavada Madhav sold $87,784 worth of shares (12,606 units at $6.96), decreasing direct ownership by 4% to 290,623 units (SEC Form 4) to cover withholding tax4 - ABEONA THERAPEUTICS INC. (0000318306) (Issuer)
ABEO FAQ
6 questionsWhat does Abeona Therapeutics Inc. do?
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead programs include EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa; ABO-102, an adeno-associated virus-based gene therapy for Sanfilippo syndrome type A; and ABO-101, an AAV-based gene therapy for Sanfilippo syndrome type B. The company also develops ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-5OX for the treatment of genetic eye disorders. In...Where does ABEO stock trade?
Abeona Therapeutics Inc. (ABEO) is listed on NASDAQ.What sector and industry is ABEO in?
Abeona Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about ABEO?
Abeona Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Roth Capital: Buy with a $1700.00 price target on 2026-09-17.What companies are similar to ABEO?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare ABEO side-by-side with any of them on Quantisnow.How can I track ABEO on Quantisnow?
Quantisnow aggregates Abeona Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ABEO to receive live email and push alerts on every new disclosure.